JP2016516016A5 - - Google Patents

Download PDF

Info

Publication number
JP2016516016A5
JP2016516016A5 JP2015561687A JP2015561687A JP2016516016A5 JP 2016516016 A5 JP2016516016 A5 JP 2016516016A5 JP 2015561687 A JP2015561687 A JP 2015561687A JP 2015561687 A JP2015561687 A JP 2015561687A JP 2016516016 A5 JP2016516016 A5 JP 2016516016A5
Authority
JP
Japan
Prior art keywords
body weight
dose
peptide
therapeutically effective
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015561687A
Other languages
English (en)
Japanese (ja)
Other versions
JP6542678B2 (ja
JP2016516016A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/021446 external-priority patent/WO2014138502A1/en
Publication of JP2016516016A publication Critical patent/JP2016516016A/ja
Publication of JP2016516016A5 publication Critical patent/JP2016516016A5/ja
Application granted granted Critical
Publication of JP6542678B2 publication Critical patent/JP6542678B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015561687A 2013-03-06 2014-03-06 心不全の治療または予防のためのニューレグリンまたはその断片の治療的投与の方法 Expired - Fee Related JP6542678B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201361773538P 2013-03-06 2013-03-06
US61/773,538 2013-03-06
US201361774553P 2013-03-07 2013-03-07
US61/774,553 2013-03-07
US201361900142P 2013-11-05 2013-11-05
US61/900,142 2013-11-05
PCT/US2014/021446 WO2014138502A1 (en) 2013-03-06 2014-03-06 Therapeutic dosing of a neuregulin or a fragment thereof for treatment or prophylaxis of heart failure

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019110381A Division JP2019194208A (ja) 2013-03-06 2019-06-13 心不全の治療または予防のためのニューレグリンまたはその断片の治療的投与の方法

Publications (3)

Publication Number Publication Date
JP2016516016A JP2016516016A (ja) 2016-06-02
JP2016516016A5 true JP2016516016A5 (OSRAM) 2017-04-27
JP6542678B2 JP6542678B2 (ja) 2019-07-10

Family

ID=50382702

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2015561687A Expired - Fee Related JP6542678B2 (ja) 2013-03-06 2014-03-06 心不全の治療または予防のためのニューレグリンまたはその断片の治療的投与の方法
JP2019110381A Pending JP2019194208A (ja) 2013-03-06 2019-06-13 心不全の治療または予防のためのニューレグリンまたはその断片の治療的投与の方法
JP2021119288A Pending JP2021169514A (ja) 2013-03-06 2021-07-20 心不全の治療または予防のためのニューレグリンまたはその断片の治療的投与の方法
JP2023069875A Pending JP2023089263A (ja) 2013-03-06 2023-04-21 心不全の治療または予防のためのニューレグリンまたはその断片の治療的投与の方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2019110381A Pending JP2019194208A (ja) 2013-03-06 2019-06-13 心不全の治療または予防のためのニューレグリンまたはその断片の治療的投与の方法
JP2021119288A Pending JP2021169514A (ja) 2013-03-06 2021-07-20 心不全の治療または予防のためのニューレグリンまたはその断片の治療的投与の方法
JP2023069875A Pending JP2023089263A (ja) 2013-03-06 2023-04-21 心不全の治療または予防のためのニューレグリンまたはその断片の治療的投与の方法

Country Status (7)

Country Link
US (3) US20160129084A1 (OSRAM)
EP (1) EP2964249A1 (OSRAM)
JP (4) JP6542678B2 (OSRAM)
AU (3) AU2014225534A1 (OSRAM)
CA (1) CA2904055A1 (OSRAM)
IL (3) IL281376B (OSRAM)
WO (1) WO2014138502A1 (OSRAM)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8086315B2 (en) 2004-02-12 2011-12-27 Asap Medical, Inc. Cardiac stimulation apparatus and method for the control of hypertension
US8165674B2 (en) 2005-03-02 2012-04-24 Backbeat Medical, Inc. Methods and apparatus to increase secretion of endogenous naturetic hormones
US7869874B2 (en) 2006-09-25 2011-01-11 G&L Consulting, Llc Methods and apparatus to stimulate heart atria
US8340763B2 (en) 2008-09-08 2012-12-25 Backbeat Medical, Inc. Methods and apparatus to stimulate heart atria
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun (Shanghai)Science & Technology Limited Compositions and methods for treating heart failure
US9008769B2 (en) 2012-12-21 2015-04-14 Backbeat Medical, Inc. Methods and systems for lowering blood pressure through reduction of ventricle filling
BR112015029293A2 (pt) 2013-05-22 2018-04-24 Zensun Shanghai Science & Tech Ltd método e kit para prevenir, tratar ou retardar uma doença ou distúrbio cardiovascular em um mamífero
CN104758922A (zh) 2014-01-03 2015-07-08 上海泽生科技开发有限公司 纽兰格林制剂的配方
CN105561298A (zh) * 2014-10-17 2016-05-11 上海泽生科技开发有限公司 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物
US10342982B2 (en) 2015-09-11 2019-07-09 Backbeat Medical, Inc. Methods and systems for treating cardiac malfunction
US20180296642A1 (en) 2015-09-25 2018-10-18 Douglas B. Sawyer Methods for treating cardiac injury
US10485658B2 (en) 2016-04-22 2019-11-26 Backbeat Medical, Inc. Methods and systems for controlling blood pressure
CN111407881A (zh) * 2019-01-07 2020-07-14 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟心肌损伤的方法和组合物
AR121035A1 (es) 2019-04-01 2022-04-13 Lilly Co Eli Compuestos de neuregulina-4 y métodos de uso
CN113289002A (zh) * 2020-02-24 2021-08-24 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延缓心力衰竭的方法和组合物
US20250339493A1 (en) * 2022-05-25 2025-11-06 Eli Lilly And Company Methods of using neuregulin-4 compounds
JP2024174269A (ja) * 2023-05-30 2024-12-16 株式会社大一商会 遊技機

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5716930A (en) 1991-04-10 1998-02-10 Ludwig Institute For Cancer Research Glial growth factors
US5530109A (en) 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
US7037888B1 (en) 1992-04-03 2006-05-02 Acorda Therapeutics, Inc. Methods for treating muscle diseases and disorders
US5912326A (en) 1995-09-08 1999-06-15 President And Fellows Of Harvard College Cerebellum-derived growth factors
JP2002515436A (ja) * 1998-05-15 2002-05-28 メルク エンド カムパニー インコーポレーテッド カリウムチャネル作働薬
US6051401A (en) 1998-07-28 2000-04-18 Bayer Corporation Methods and constructs for protein expression
US6635249B1 (en) 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
CA2644804A1 (en) * 2006-03-09 2007-09-13 Waratah Pharmaceuticals Inc. A cyclohexane polyalcohol formulation for treatment of disorders of protein aggregation
ES2596262T3 (es) * 2007-09-12 2017-01-05 Merz Pharma Gmbh & Co. Kgaa Derivados de 1-amino-alquilciclohexano para su uso en el tratamiento de tinnitus asociado con pérdida de audición
EP3632459A1 (en) * 2008-07-17 2020-04-08 Acorda Therapeutics, Inc. Therapeutic dosing of a neuregulin or a subsequence thereof for treatment or prophylaxis of heart failure
EP2808339B1 (en) * 2008-11-28 2017-02-15 Zensun (Shanghai) Science & Technology, Co., Ltd. Neuregulin peptides and their use
SI3409274T1 (sl) * 2008-12-22 2020-03-31 Novartis Ag Režim odmerjanja za S1P receptor agonist
JP5677322B2 (ja) * 2009-02-04 2015-02-25 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 血糖コントロールのための情報を提供するための医療システム及び方法
CA2794147A1 (en) * 2010-03-29 2011-10-06 Abraxis Bioscience, Llc Use of a composition comprising nanoparticles comprising a taxane and an albumin to improve uptake of chemotherapeutics by tumors and for treating a cancer that is highly fibrotic and/or has a dense stroma
PH12014500122A1 (en) * 2011-07-13 2014-03-24 Pharmacyclics Inc Inhibitors of bruton's tyrosine kinase

Similar Documents

Publication Publication Date Title
JP2016516016A5 (OSRAM)
JP2020033360A5 (OSRAM)
JP2013533858A5 (OSRAM)
JP2015187125A5 (OSRAM)
JP2020529996A5 (OSRAM)
MX2014006547A (es) Tratamiento combinado del cancer.
JP2015532293A5 (ja) 糖尿病患者における心不全の治療用組成物
MX2017012506A (es) Composicion farmaceutica para la prevencion y tratamiento de enfermedades del ojo que contiene, como ingrediente activo, una proteina de fusion en la cual el peptido que penetra el tejido y la preparacion del factor de crecimiento endotelial antivascular se fusionan.
JP2013541583A5 (OSRAM)
RU2013123646A (ru) Комбинированная композиция
JP2017501154A5 (OSRAM)
RU2016149316A (ru) Лечение ревматоидного артрита
JP2020536121A5 (OSRAM)
PH12015502465A1 (en) Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias
JP2016505050A5 (OSRAM)
JP2019507786A5 (OSRAM)
RU2017126212A (ru) Композиция
Wedemeyer et al. 96 weeks of pegylated-Interferon-alpha-2a plus tenofovir or placebo for the treatment of hepatitis delta: the HIDIT-2 study: 31
JP2016510040A5 (OSRAM)
JP2017502058A5 (OSRAM)
JP2019535830A5 (OSRAM)
JPWO2020033768A5 (OSRAM)
RU2018132694A (ru) Фармацевтическая композиция, включающая рекомбинантный гормон роста человека для лечения дефицита гормона роста
JP2019504040A (ja) 中等度〜重度のインフルエンザの処置
JP2017508455A5 (OSRAM)